Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Thornton, Colorado Clinical Trials

A listing of Thornton, Colorado clinical trials actively recruiting patient volunteers.

RESULTS

Found (41) clinical trials

Atezolizumab Pemetrexed Disodium Cisplatin and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

PRIMARY OBJECTIVES: I. To evaluate if the regimen of neoadjuvant cisplatin-pemetrexed disodium (pemetrexed)-atezolizumab, surgery +/- radiation, then maintenance atezolizumab is feasible and safe for patients with resectable malignant pleural mesothelioma. SECONDARY OBJECTIVES: I. To evaluate progression free survival (both by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 and also ...

Phase

1.71 miles

Learn More »

Iloprost in Preventing Lung Cancer in Former Smokers

PRIMARY OBJECTIVES: I. To evaluate the toxicity of inhalational iloprost administered to cohorts of patients daily for 2 months, given four times a day (QID) in Cohort A followed by twice daily (BID) in Cohort B. SECONDARY OBJECTIVES: I. To evaluate the compliance with BID or QID dosing regimens. II. ...

Phase

6.58 miles

Learn More »

A First in Human Dose Escalation Study of JAB-3068 in Adult Patients With Advanced Solid Tumors

This is a phase 1, multi-center, dose escalation, open-label study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of JAB-3068 in adult patients with advanced solid.

Phase

8.31 miles

Learn More »

A Phase 1 Study of TSR-022 an Anti-TIM-3 Monoclonal Antibody in Patients With Advanced Solid Tumors

This is a multicenter, open-label, first-in-human Phase 1 study evaluating the anti-TIM-3 (T cell immunoglobulin and mucin containing protein-3) antibody TSR-022, as a monotherapy and in combination with an anti-PD-1 antibody, in patients with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 ...

Phase

8.95 miles

Learn More »

M6620 First in Human Study

An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics (PK) of M6620 in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors

Phase

8.95 miles

Learn More »

A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma

Study RGX-104-001 is a Phase 1, first-in-human, dose escalation and expansion study of RGX-104, an oral small molecule targeting the liver X receptor (LXR), as a single agent and in combination with nivolumab. RGX-104 activates LXR, resulting in depletion of both myeloid-derived suppressor cells (MDSCs) as well as tumor blood ...

Phase

9.35 miles

Learn More »

The Safety Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors

The Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors

Phase

9.35 miles

Learn More »

Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer

During the Phase 1 segment, the dose and regimen of MGCD516 will be assessed. During the Phase 1b segment, the clinical activity of MGCD516 will be evaluated in selected patient populations. Patients anticipated to be enrolled in Phase 1b will be selected based upon the following cancer diagnosis: Non-small cell ...

Phase

9.35 miles

Learn More »

A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer

This is an open-label, Phase 1b dose escalation and expansion study of OMP-305B83 plus FOLFIRI or FOLFOX to evaluate the safety, efficacy, and pharmacokinetics of OMP-305B83 in combination with FOLFIRI or FOLFOX in patients with metastatic Colorectal Cancer. This study consists of a screening period, a treatment period, and a ...

Phase

9.35 miles

Learn More »

P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)

The study will follow a 3 + 3 design of dose-escalating cohorts. After a patient enrolls, leukapheresis will be performed to obtain peripheral blood mononuclear cells which will be sent to a manufacturing site to produce P-BCMA-101 CAR-T cells. The cells will then be returned to the investigational site and, ...

Phase

9.35 miles

Learn More »